Adaptive Biotechnologies plans separation of immune medicine platform
Adaptive Biotechnologies plans separation of immune medicine platform June 15 (Reuters) - Adaptive Biotechnologies ADPT.O said on Monday it planned to separate its immune medicine business from its residual cancer-testing unit, as it reviews options for the drug-discovery business and focuses on testing.
The company said it was reviewing options for the immune medicine business and expected to choose a preferred path by the end of 2026.
Adaptive's immune medicine platform helps conduct drug research by identifying therapeutic targets, and accelerate the development of precision medicines.
Adaptive said the residual cancer-testing unit, which includes its clonoSEQ test, had reached profitability and expanded insurance coverage.
ClonoSEQ is used to detect small traces of cancer that may remain after treatment and is also used in drug-development studies.
The unit's revenue rose to $212 million in 2025 from $103 million in 2023, the company said.
Adaptive said the immune medicine business might be better placed outside the company's diagnostics-focused model.
The company said there was no assurance the review would result in a deal or any other outcome.
(Reporting by Kunal Das in Bengaluru; Editing by Anil D'Silva)
((Kunal.Das2@thomsonreuters.com;))
Recent news on Adaptive Biotechnologies
See all newsBrief: Adaptive Biotechnologies Corp - Issues $345 Million In 0% Convertible Senior Notes Due 2031 - SEC Filing
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, CME
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobile